

Noninvasive assessment of liver fibrosis: key messages

Polish Archives of Internal Medicine

124, 329-335

DOI: [10.20452/pamw.2301](https://doi.org/10.20452/pamw.2301)

Citation Report

#	ARTICLE	IF	CITATIONS
1	Cytokeratin 18-Aspartate396 apoptotic fragment for fibrosis detection in patients with non-alcoholic fatty liver disease and chronic viral hepatitis. <i>Digestive and Liver Disease</i> , 2016, 48, 55-61.	0.4	19
2	Prognostic Role of Serum Cytokeratin-19 Fragment (CYFRA 21-1) in Patients with Hepatocellular Carcinoma. <i>Cancers</i> , 2020, 12, 2776.	1.7	14
3	Alpha-Fetoprotein, Protein Induced by Vitamin K Absence or Antagonist II and Glypican-3 for the Detection and Prediction of Hepatocellular Carcinoma in Patients with Cirrhosis of Viral Etiology. <i>Cancers</i> , 2020, 12, 3218.	1.7	27
4	The Clinical Role of Serum Epidermal Growth Factor Receptor 3 in Hepatitis C Virus-Infected Patients with Early Hepatocellular Carcinoma. <i>Biology</i> , 2021, 10, 215.	1.3	4
5	Chronic hepatitis B virus infection and fibrosis: novel non-invasive approaches for diagnosis and risk stratification. <i>Minerva Gastroenterology</i> , 2022, 68, .	0.3	2
6	Elastography for characterization of focal liver lesions: current evidence and future perspectives. <i>Minerva Gastroenterology</i> , 2021, 67, .	0.3	9
7	Biomarkers of Oncogenesis, Adipose Tissue Dysfunction and Systemic Inflammation for the Detection of Hepatocellular Carcinoma in Patients with Nonalcoholic Fatty Liver Disease. <i>Cancers</i> , 2021, 13, 2305.	1.7	24
8	Usefulness of a Hepatitis B Surface Antigen-Based Model for the Prediction of Functional Cure in Patients with Chronic Hepatitis B Virus Infection Treated with Nucleos(t)ide Analogues: A Real-World Study. <i>Journal of Clinical Medicine</i> , 2021, 10, 3308.	1.0	6
9	Management of primary biliary cholangitis prior to obeticholic acid availability. <i>Minerva Medica</i> , 2018, 109, 410-417.	0.3	7
10	Alcoholic liver fibrosis: detection and treatment. <i>Minerva Medica</i> , 2018, 109, 457-471.	0.3	37
11	Diagnostic accuracy of non-invasive methods detecting clinically significant portal hypertension in liver cirrhosis: a systematic review and meta-analysis. <i>Minerva Medica</i> , 2020, 111, 266-280.	0.3	4
12	Moving towards core antigen for the management of patients with overt and occult HBV infection. <i>Panminerva Medica</i> , 2020, , .	0.2	4
13	Prediction of Hepatic Fibrosis in Patients with Chronic Hepatitis C Genotype 4: A Non-Invasive Biochemical Analysis. <i>Biosciences, Biotechnology Research Asia</i> , 2016, 13, 287-297.	0.2	0
14	Liver stiffness-based model for portal hypertension and hepatocellular cancer risk in HBV responsive to antivirals. <i>Minerva Gastroenterologica E Dietologica</i> , 2019, 65, 11-19.	2.2	5
15	Relationships between ultrasonic, immunological changes in the progression of liver steatosis and fibrosis in patients with chronic diffusive liver diseases of various etiologies. <i>Patologia</i> , 2019, .	0.1	0
16	Liver fibrosis in NAFLD patients: examining the opportunity to find a non-invasive, accurate and low-cost tool. <i>Minerva Gastroenterology</i> , 2022, 67, .	0.3	4
17	Effect of COVID-19 Pandemic on Hepatocellular Carcinoma Diagnosis: Results from a Tertiary Care Center in North-West Italy. <i>Current Oncology</i> , 2022, 29, 1422-1429.	0.9	11
18	The evolution in the search for biomarkers of liver diseases. <i>Gazzetta Medica Italiana Archivio Per Le Scienze Mediche</i> , 2022, 180, .	0.0	0

#	ARTICLE	IF	CITATIONS
19	Elastography for characterization of focal liver lesions: current evidence and future perspectives. <i>Minerva Gastroenterology</i> , 2021, 67, 196-208.	0.3	3
20	Liver Cancer-Specific Isoform of Serine Protease Inhibitor Kazal for the Detection of Hepatocellular Carcinoma: Results from a Pilot Study in Patients with Dysmetabolic Liver Disease. <i>Current Oncology</i> , 2022, 29, 5457-5465.	0.9	3
21	Clinical importance of laboratory biomarkers in liver fibrosis. <i>Biochemia Medica</i> , 2022, 32, 346-356.	1.2	5
22	Serum glypican-3 for the prediction of survival in patients with hepatocellular carcinoma. <i>Minerva Gastroenterology</i> , 2022, 68, .	0.3	3